Literature DB >> 12231103

Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.

Chamberlain I Obialo1, Elizabeth O Ofili, Tariq Mirza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12231103     DOI： 10.1016/s0002-9149(02)02581-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  11 in total

1.  Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.

Authors:  Eike Wrenger; Regina Müller; Michael Moesenthin; Tobias Welte; Jürgen C Frölich; Klaus H Neumann
Journal:  BMJ       Date:  2003-07-19

2.  Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.

Authors:  Jörg Indermitte; Sabine Burkolter; Jürgen Drewe; Stephan Krähenbühl; Kurt E Hersberger
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Pharmacotherapy of heart failure in the elderly: adverse events.

Authors:  Michael W Rich
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

4.  New prescriptions of spironolactone associated with angiotensin-converting-enzyme inhibitors and/or angiotensin receptor blockers and their laboratory monitoring from 2001 to 2008: a population study on older people living in the community in Italy.

Authors:  Claudio Bilotta; Carlotta Franchi; Alessandro Nobili; Paola Nicolini; Codjo Djignefa Djade; Mauro Tettamanti; Ida Fortino; Angela Bortolotti; Luca Merlino; Carlo Vergani
Journal:  Eur J Clin Pharmacol       Date:  2012-09-21       Impact factor: 2.953

5.  Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.

Authors:  Giampiero Giovacchini; Guillaume Nicolas; Heike Freidank; Thomas L Mindt; Flavio Forrer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

6.  The frequency of hyperkalemia and its significance in chronic kidney disease.

Authors:  Lisa M Einhorn; Min Zhan; Van Doren Hsu; Lori D Walker; Maureen F Moen; Stephen L Seliger; Matthew R Weir; Jeffrey C Fink
Journal:  Arch Intern Med       Date:  2009-06-22

7.  Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases.

Authors:  Omalhassan Amir; Yahaya Hassan; Azmi Sarriff; Ahmed Awaisu; Noorizan Abd Aziz; Omar Ismail
Journal:  Pharm World Sci       Date:  2009-03-03

8.  Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

9.  New treatments for hyperkalaemia: clinical use in cardiology.

Authors:  Shilpa Vijayakumar; Javed Butler; Stefan D Anker
Journal:  Eur Heart J Suppl       Date:  2019-02-26       Impact factor: 1.803

Review 10.  Well tolerated spironolactone-related hyponatremia.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.